By Susan Kelly and Debra Sherman

CHICAGO (Reuters) - Twin setbacks for St Jude Medical Inc's heart rhythm devices are raising concerns on Wall Street that doctors will curb use of the company's products, weakening its position in the $6.5 billion global market for implantable defibrillators.